For decades, the dominant theory of Parkinson’s disease progression has held that misfolded alpha-synuclein protein spreads from cell to cell through the brain, gradually destroying the dopamine neurons that control movement. But the molecular machinery that allows this spread has remained unknown, until now.
A team led by Stephen M. Strittmatter at Yale School of Medicine, publishing in Nature Communications, has identified the cell-surface complex that lets misfolded alpha-synuclein enter healthy dopamine neurons: a partnership between two proteins called mGluR4 and NPDC1. When either protein is disabled in mice, the cascade of neurodegeneration is halted.
The discovery pipeline
The researchers conducted an unbiased screen of 4,401 membrane proteins, more than 80% of all proteins annotated to the cell surface, expressing each in HEK293T cells and testing whether biotin-labeled alpha-synuclein fibrils would bind. Only 16 proteins showed binding activity. The top candidates were mGluR4 (metabotropic glutamate receptor 4) and NPDC1 (Neuronal Proliferation, Differentiation and Control 1).
The choice proved strategic. Roughly 98% of tyrosine hydroxylase-positive neurons in the substantia nigra pars compacta, the very cells that die in Parkinson’s, co-express both proteins. mGluR4 binds alpha-synuclein fibrils with a dissociation constant of 33 nanomolar; NPDC1 binds at 80 nanomolar. Neither binds monomeric alpha-synuclein, and neither binds the fibrils of other proteins. The specificity is remarkable.
How they work together
mGluR4 and NPDC1 form a physical complex on the cell surface. NPDC1 blocks mGluR4’s normal calcium-signaling function and provides the extracellular N-terminal domain that directly binds alpha-synuclein fibrils. When co-expressed, the two proteins dramatically boost fibril binding relative to either alone.
Genetic interaction experiments confirmed the functional partnership: mice missing one copy of either gene (single heterozygotes) showed no protection against alpha-synuclein toxicity. But mice missing one copy of both genes (double heterozygotes) showed markedly reduced fibril binding, reduced phosphorylated alpha-synuclein accumulation, and reduced synapse loss.
Blocking spread in mice
Two complementary mouse models were tested. In the first, a seeding model in which alpha-synuclein fibrils are injected directly into the striatum, knockout of either mGluR4 or NPDC1 completely prevented dopamine neuron loss in the substantia nigra. In wild-type mice, the injection caused severe neuron death. In the knockouts, the protection was statistically robust (p < 0.0001).
In the second model, A53T transgenic mice, which carry a genetic mutation known to cause Parkinson’s, the results were even more striking. Double heterozygous or double knockout mice showed significantly improved survival, fully rescued grip strength, and complete prevention of spinal motor neuron loss, despite persistent alpha-synuclein accumulation. The protective effect was downstream of aggregation: the protein still clumped, but the toxicity was blocked.
A druggable target
The significance of the finding lies not just in identifying the mechanism, but in the nature of the target. mGluR4 is a GPCR, a class of proteins for which there are already approved drugs. Orthosteric ligands such as glutamate and the experimental compound L-AP4 reduce alpha-synuclein fibril binding, suggesting that existing mGluR4 modulators could potentially be repurposed.
Because the mGluR4-NPDC1 complex sits on the cell surface and is expressed almost exclusively on the vulnerable dopamine neurons, a therapy targeting it could be both accessible and specific.
The finding opens the door to the first disease-modifying treatment for Parkinson’s, which affects roughly 1.1 million Americans with 90,000 new cases each year. Current therapies treat symptoms only.
Sources
[1] Perez-Canamas, A., Chen, M., Almandoz-Gil, L., et al. “mGluR4–NPDC1 complex mediates alpha-synuclein fibril-induced neurodegeneration.” Nature Communications, Vol. 17(1), 994 (2025). DOI: 10.1038/s41467-025-67731-3
[2] ScienceDaily. “Yale identifies how Parkinson’s spreads through the brain.” (2026). https://www.sciencedaily.com/releases/2026/07/260710003529.htm